What does MORIASFARMA do?

MORIASFARMA is filed with the CBE under the catch-all “Overige zakelijke dienstverlening”, a code that says little about what the company actually does. Private Limited, started on 12 January 2005, 1 establishment.

What is the address of MORIASFARMA?

The registered office of MORIASFARMA is located at Assestraat 105, 1700 Dilbeek.

Is MORIASFARMA still active?

Yes. According to the CBE (17 September 2026) MORIASFARMA is active, legal situation “Normale toestand”, started on 12 January 2005.

Is MORIASFARMA registered on Peppol?

Yes, MORIASFARMA is registered on the Peppol network with ID 0208:0871162146.

What is the enterprise number of MORIASFARMA?

The enterprise number of MORIASFARMA is BE0871162146.

When was MORIASFARMA founded?

MORIASFARMA was founded on 12 January 2005.

Who are the directors of MORIASFARMA?

According to the 2025 annual accounts, the directors of MORIASFARMA are: Dirk MORIAS.

Is MORIASFARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 12 January 2005; 5 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did MORIASFARMA make in 2025?

MORIASFARMA posted a profit after taxes of € 76,427 in financial year 2025.

What is the revenue of MORIASFARMA?

As a small company, MORIASFARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 78,265.

MORIASFARMA (Private Limited) - Dilbeek - BE0871162146

Dossier MORIASFARMA, printed on 17 September 2026 from databakkes.be/en/0871162146/moriasfarma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

MORIASFARMA from Dilbeek, company number BE0871162146, closed financial year 2025 with a result of € 76,427 after tax. For that financial year MORIASFARMA recorded a gross margin of € 78,265 and equity of € 651,008. Compared with financial year 2024, the result moved from € 82,744 to € 76,427. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on July 23, 2026.

What it is worth Growing

€ 651,008

▲ 13% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Healthy

€ 76,427

▼ 8% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 521

▼ 63% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 632,408.

Debts at end 2025

Bank debt ≈ 31 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 509,572

▼ 12% vs 2024

€ 16,572 is repaid this year. At this pace the long-term loan is gone in ≈ 31 years.

Owed to suppliers

€ 1,261

▼ 90% vs 2024

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 20,058

▲ 54% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 16,098 Gross margin 2022: € 16,098 First fiscal year in the series	€ 48,009 Gross margin 2023: € 48,009 ▲ 198% vs 2022 (€ 16,098) Favourable step	€ 55,719 Gross margin 2024: € 55,719 ▲ 16% vs 2023 (€ 48,009) Favourable step	€ 78,265 Gross margin 2025: € 78,265 ▲ 40% vs 2024 (€ 55,719) Favourable step	▲ 40%
Profit after taxes	€ 54,479 Profit after taxes 2022: € 54,479 First fiscal year in the series	€ 74,446 Profit after taxes 2023: € 74,446 ▲ 37% vs 2022 (€ 54,479) Favourable step	€ 82,744 Profit after taxes 2024: € 82,744 ▲ 11% vs 2023 (€ 74,446) Favourable step	€ 76,427 Profit after taxes 2025: € 76,427 ▼ 8% vs 2024 (€ 82,744) Unfavourable step	▼ 8%
Equity	€ 568,592 Equity 2022: € 568,592 First fiscal year in the series	€ 491,838 Equity 2023: € 491,838 ▼ 13% vs 2022 (€ 568,592) Unfavourable step	€ 574,581 Equity 2024: € 574,581 ▲ 17% vs 2023 (€ 491,838) Favourable step	€ 651,008 Equity 2025: € 651,008 ▲ 13% vs 2024 (€ 574,581) Favourable step	▲ 13%
Total debts	€ 574,020 Total debts 2022: € 574,020 First fiscal year in the series	€ 677,146 Total debts 2023: € 677,146 ▲ 18% vs 2022 (€ 574,020) Unfavourable step	€ 644,588 Total debts 2024: € 644,588 ▼ 5% vs 2023 (€ 677,146) Favourable step	€ 613,969 Total debts 2025: € 613,969 ▼ 5% vs 2024 (€ 644,588) Favourable step	▼ 5%
Cash	€ 3,821 Cash 2022: € 3,821 First fiscal year in the series	€ 17 Cash 2023: € 17 ▼ € 3,804 vs 2022 (€ 3,821) Unfavourable step	€ 1,412 Cash 2024: € 1,412 ▲ € 1,395 vs 2023 (€ 17) Favourable step	€ 521 Cash 2025: € 521 ▼ 63% vs 2024 (€ 1,412) Unfavourable step	▼ 63%
Retained profit	€ 398,792 Retained profit 2022: € 398,792 First fiscal year in the series	€ 473,238 Retained profit 2023: € 473,238 ▲ 19% vs 2022 (€ 398,792) Favourable step	€ 555,981 Retained profit 2024: € 555,981 ▲ 17% vs 2023 (€ 473,238) Favourable step	€ 632,408 Retained profit 2025: € 632,408 ▲ 14% vs 2024 (€ 555,981) Favourable step	▲ 14%
Bank debt	€ 561,671 Bank debt 2022: € 561,671 First fiscal year in the series	€ 633,359 Bank debt 2023: € 633,359 ▲ 13% vs 2022 (€ 561,671) Unfavourable step	€ 577,558 Bank debt 2024: € 577,558 ▼ 9% vs 2023 (€ 633,359) Favourable step	€ 509,572 Bank debt 2025: € 509,572 ▼ 12% vs 2024 (€ 577,558) Favourable step	▼ 12%
Balance sheet total	€ 1,142,612 Balance sheet total 2022: € 1,142,612 First fiscal year in the series	€ 1,168,983 Balance sheet total 2023: € 1,168,983 ▲ 2% vs 2022 (€ 1,142,612) Unchanged	€ 1,219,169 Balance sheet total 2024: € 1,219,169 ▲ 4% vs 2023 (€ 1,168,983) Unchanged	€ 1,264,977 Balance sheet total 2025: € 1,264,977 ▲ 4% vs 2024 (€ 1,219,169) Unchanged	▲ 4%

Key figures of MORIASFARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to MORIASFARMA?

What happened at MORIASFARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jul 23, 2026 New annual accounts for financial year 2025: profit of € 76,427 (▼ 8% vs 2024). Source: NBB ↗
May 26, 2005 New establishment in Sint-Agatha-Berchem. KBO
Jan 12, 2005 Start of the company according to the CBE. KBO

In short

From € 54,479 profit in 2022 to € 76,427 profit in 2025.

Paid € 73,097 in corporate taxes since 2022.

Best year ever: 2024, with € 82,744 profit.

Original PDFs at the National Bank ↗

A new publication or filing at MORIASFARMA? We notify you, reason included.

Follow MORIASFARMA

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit